Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosol BCG Challenge in Historically Vaccinated Adults
NCT04777721Phase 1Completed
- Sponsor
- University of Oxford
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of bacillus calmette-guerin substrain danish 1331 live antigen in Tuberculosis (TB) (4 arms), sponsored by University of Oxford. Primary endpoint: Quantify BCG Recoverable From Bronchial Sample at Day 14. Started May 2022; status: completed.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigen
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04777721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777721.